FDA grants Promedior Inc. to study antififistosis immunomodulator PRM-151 breakthrough therapy

today, Promedior(http://announced that the U.SFDA(http://granted the company's pre-development anti-fibromy immunomodulator PRM-151 breakthrough therapy for the treatment of iasevere pulmonary fibrosis (IPF)PRM-151 is a recombinant form of endogenous positive pentaprotein 2 (pentraxin-2, PTX-2)It activates the ability of macrophages to eliminate fibrosis tissuePromedior has recently reached a consensus with the FDA on the design of the http://of the Phase 3 ClinicalTrial
trial design for PRM-151About PRM-151The PRM-151 developed by Promedior is a recombinant protein for PTX-2PTX-2 is an endogenous immunomodulation protein that regulates mononucleocytes in the human bodyPRM-151 is able to specifically bind to cell and tissue residues in the microenvironment of damaged tissue, and can promote their differentiation to eliminate macrophages in fibrosis tissue by binding to mononucleosis, rather than promoting inflammatory responses and fibrosis macrophages typesPRM-151 has been active in a variety of preclinical models of fibrosis diseases, including pulmonary fibrosis, bone marrow fibrosis, acute and chronic kidney disease, liver fibrosis, and age-related macular degeneration In Phase 2 clinical trials involving 117 IPF patients, the mandatory lung capacity (FVC) and 6-minute walking distance (6MWD) indicators of patients treated with PRM-151 were significantly better than those in the control group After 28 weeks of treatment, the PRM-151 group of 6MWD decreased by an average of 0.5 m, while the 6MWD in the placebo group decreased by an average of 31 m (p.001) The almost unchanged results of the 6MWD index in the prM-151 group were very rare, demonstrating the overall functional benefits of this therapy for IPF patients